N/A N=75 Medtronic RESOLUTE ONYX Core (2.25 mm - 4.0 mm) Clinical Study
Coronary Artery Disease
Primary: In-stent Late Lumen Loss as Measured by Quantitative Coronary Angiography — 0.24 mm
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=18 Clopidogrel Pharmacogenetics (PGX) Bench to Bedside
Metabolism of Clopidogrel
Primary: Change in Platelet Aggregation Following Therapy With Clopidogrel — 62.9; 68.1; 62.5; 63.2 percentage of aggregation
N/A N=18 Rainbow DCI vs. R1-25 Sensor SpHb Sub-Range Performance Equivalence
Healthy
Primary: Sub-Range Performance Equivalence of Rainbow DCI and R1-25 Sensors by ARMS Calculation — 1.2; 1.2 g/dL
Phase 2 N=64 RDEA3170 and Febuxostat Combination Study in Gout Subjects
Gout
Primary: Serum Urate Maximum Percentage (%) Change (Emax, CB) — -43.5; -55.6; -70.4; -79.1 Percentage (%) — p=<0.0001
Phase 2 N=21 Study of RADPLAT and Tarceva in Locally Advanced Head and Neck Squamous Cell Carcinoma (SCCA)
Head and Neck Cancer
Primary: Number of Participants With Complete and Partial Response Using RECIST Criteria — 17; 2 Participants
Phase 4 N=125 The Efficacy and Safety Study of Rikkunshito in Patients With Functional Dyspepsia
Functional Dyspepsia
Primary: Patient's Evaluation of Symptomatic Improvement by Overall Treatment Efficacy (OTE) — 1; 5; 13; 18 Participants — p=0.038
N/A N=136 Clinical Comparison of 27+® and 23-gauge ULTRAVIT® 7500 Cpm Vitrectomy Outcomes
Vitreoretinal Disease
Primary: Mean Change in Intraocular Pressure (IOP) on Operative Day — -0.40; -3.05 mmHG
N/A N=28 Accuracy of Methemoglobin Measurement of Various Rainbow Pulse Oximeter Sensors
Healthy
Primary: Accuracy of Methemoglobin Measurement by Arms Calculation — 0.48 percentage of total hemoglobin
Phase 3 N=160 Coadministration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) With Ribavirin (RBV) in Adults With Genotype 4 (GT4) Hepatitis C Virus (HCV) in Egypt
HCV · Hepatitis C Infection · Genotype 4
Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12) in Each Treatment Arm — 94.0; 96.8; 93.1 percentage of participants
N/A N=21 Rainbow R2-25 vs. R1-25 SpHb Sub-Range Performance Equivalence
Healthy
Primary: Sub-Range Performance Equivalence of R2-25 and R1-25 Sensors by ARMS Calculation — 1.33; 1.41 g/dL
Phase 3 N=231 LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib
Non-Small Cell Lung Cancer
Primary: Progression Free Survival (PFS) Per Blinded Independent Review Committee (BIRC) — 5.4; 1.6 months — p=<0.001
N/A N=89 SMBG Protocols Predicting Glucose Levels in Senior Diabetes Mellitus With CAD
Diabetes Mellitus, Type 2 · Coronary Artery Disease
Primary: Evaluation of Peak and Nadir Glucose Profiles From Continuous Glucose Monitoring System (CGMS) — 8.86; 8.72; 8.80; 6.87 mmol/L
Phase 2 N=22 Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer
Recurrent Uterine Corpus Sarcoma · Uterine Carcinosarcoma
Primary: Objective Tumor Response (Complete or Partial) — 0 percentage of participants
N/A N=30 Observational Study to Evaluate the Effectiveness and Safety of the Dexcom G4 Continuous Glucose Monitoring System in Pediatrics
Diabetes Mellitus
Primary: Point Accuracy of CGM ISF Readings to Blood Glucose Measured by a Reference Device — 77 Percentage of matched pairs w/i %20/20
Phase 4 N=121 Carvedilol as an Adjunct to Endoscopic Cyanoacrylate Injection for Secondary Prophylaxis of Gastric Variceal Bleeding
Esophageal and Gastric Varices
Primary: Rebleeding From Gastric Varices — 14; 21 Participants